Ionis Pharmaceuticals, Inc. (IONS) Chairman Stanley T. Crooke Sells 11000 Shares

Ionis Pharmaceuticals Inc Growing Royalties an Advancing Pipeline and Getting Back Rights to Some Drugs

Ionis Pharmaceuticals Inc Growing Royalties an Advancing Pipeline and Getting Back Rights to Some Drugs

The shares were sold at an average price of $52.10, for a total value of $859,650.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has risen 32.81% since August 11, 2016 and is uptrending. During trading sessions, stock movements can seem like a popularity contest from time to time.

The company is trading up by 1.80 percent from yesterday's close.

(NASDAQ:IONS) in a research report released on Wednesday, July 12th. The company reported ($0.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.03. The business had revenue of $104.15 million for the quarter, compared to analysts' expectations of $93.29 million. Ionis Pharmaceuticals had a return on equity of 17.34% and a net margin of 5.25%. The business's revenue for the quarter was up 170.7% compared to the same quarter previous year. On average, equities research analysts anticipate that Ionis Pharmaceuticals will post ($0.02) EPS for the current year. The 50 day moving average moved down $-6.46 and the 200 day average was down $-0.62.

TRADEMARK VIOLATION NOTICE: This article was posted by Week Herald and is the property of of Week Herald. If you are accessing this report on another domain, it was illegally stolen and republished in violation of global copyright legislation. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/11/ionis-pharmaceuticals-inc-ions-chairman-sells-608850-00-in-stock-updated-updated.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Also Prnewswire.com published the news titled: "Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast" on July 25, 2017. Parallel Advisors LLC now owns 2,073 shares of the company's stock worth $109,000 after buying an additional 800 shares in the last quarter. Comerica Bank now owns 16,505 shares of the company's stock valued at $794,000 after buying an additional 4,122 shares in the last quarter. Westpac Banking Corp bought a new position in Ionis Pharmaceuticals during the first quarter worth approximately $171,000. Hanseatic Management Services Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth about $138,000. Vanguard Group Inc. now owns 9,437,796 shares of the company's stock valued at $379,399,000 after buying an additional 384,830 shares in the last quarter.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. The firm has "Market Perform" rating by BMO Capital Markets given on Friday, May 27. Vetr downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating and set a $37.67 price target for the company.in a research report on Monday, April 3rd.

Separately, Stifel Nicolaus initiated coverage on shares of Akcea Therapeut in a research report on Tuesday.

BMO Capital Markets reaffirmed their outperform rating on shares of Ionis Pharmaceuticals, Inc. They now have a $62.00 target price on the stock, up from their prior target price of $59.00.